標(biāo)題: Titlebook: Compulsory Patent Licensing and Access to Medicines: A Silver Bullet Approach to Public Health?; Van Anh Le Book 2022 The Editor(s) (if ap [打印本頁(yè)] 作者: genial 時(shí)間: 2025-3-21 19:34
書目名稱Compulsory Patent Licensing and Access to Medicines: A Silver Bullet Approach to Public Health?影響因子(影響力)
書目名稱Compulsory Patent Licensing and Access to Medicines: A Silver Bullet Approach to Public Health?影響因子(影響力)學(xué)科排名
書目名稱Compulsory Patent Licensing and Access to Medicines: A Silver Bullet Approach to Public Health?網(wǎng)絡(luò)公開度
書目名稱Compulsory Patent Licensing and Access to Medicines: A Silver Bullet Approach to Public Health?網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Compulsory Patent Licensing and Access to Medicines: A Silver Bullet Approach to Public Health?被引頻次
書目名稱Compulsory Patent Licensing and Access to Medicines: A Silver Bullet Approach to Public Health?被引頻次學(xué)科排名
書目名稱Compulsory Patent Licensing and Access to Medicines: A Silver Bullet Approach to Public Health?年度引用
書目名稱Compulsory Patent Licensing and Access to Medicines: A Silver Bullet Approach to Public Health?年度引用學(xué)科排名
書目名稱Compulsory Patent Licensing and Access to Medicines: A Silver Bullet Approach to Public Health?讀者反饋
書目名稱Compulsory Patent Licensing and Access to Medicines: A Silver Bullet Approach to Public Health?讀者反饋學(xué)科排名
作者: Notify 時(shí)間: 2025-3-21 23:11
International Patent Law and the Pharmaceutical Industry,ry, and to highlight the benefits and disbenefits associated with patent innovation. As will be critically evaluated in this chapter, the international patent system, from the Paris Convention to the TRIPS Agreement, has been significantly bolstered. To the world’s pharmaceutical industry, TRIPS is 作者: 背景 時(shí)間: 2025-3-22 03:05 作者: Heterodoxy 時(shí)間: 2025-3-22 06:29 作者: 靈敏 時(shí)間: 2025-3-22 10:36 作者: Medley 時(shí)間: 2025-3-22 14:37
Access to Medicines and Multilateral Organisations,ich in one way or another all take part in the ongoing deliberations of access to medicine. This chapter aims at establishing and analysing the stance of the four aforementioned organisations and determines to what extent their roles influence the world’s access to medicine policies, particularly th作者: Medley 時(shí)間: 2025-3-22 19:26 作者: meritorious 時(shí)間: 2025-3-22 23:58
IPS flexibilities.This timely monograph focuses on India and Brazil’s use of compulsory licensing, one of the most significant and controversial TRIPS flexibilities. This is a topical work at this critical time when the COVID-19 has stirred up the debate about compulsory licensing and access to medi作者: neolith 時(shí)間: 2025-3-23 01:34
https://doi.org/10.1007/978-3-531-91596-8wned by Bayer. While this historic decision seemed to herald a new era of compulsory licensing in the region, the Controller, unexpectedly, turned down two subsequent applications made by private companies, in late 2013 and early 2016. By examine these three applications, this chapter is to yield new insights into the Indian situation.作者: 逢迎白雪 時(shí)間: 2025-3-23 09:12
The Indian Case Study of Compulsory Licensing,wned by Bayer. While this historic decision seemed to herald a new era of compulsory licensing in the region, the Controller, unexpectedly, turned down two subsequent applications made by private companies, in late 2013 and early 2016. By examine these three applications, this chapter is to yield new insights into the Indian situation.作者: malapropism 時(shí)間: 2025-3-23 10:49 作者: 可互換 時(shí)間: 2025-3-23 15:59
International Patent Law and the Pharmaceutical Industry,a giant leap in harmonising patentability because it not only eliminates discrepancies in patent laws across countries but also creates the protection for medicine patents which were not protected before.作者: Nomadic 時(shí)間: 2025-3-23 18:06 作者: Fulminate 時(shí)間: 2025-3-24 00:57 作者: 粗鄙的人 時(shí)間: 2025-3-24 05:30
The Brazilian Case Study of Compulsory Licensing,e Brazilian model” and strongly recommended in other countries. This chapter provides an in-depth review of Brazil’s compulsory licensing, arguing that following the Brazilian model should be treated with caution.作者: 完整 時(shí)間: 2025-3-24 06:57
The Bilingualism Controversy: Les Préludesa giant leap in harmonising patentability because it not only eliminates discrepancies in patent laws across countries but also creates the protection for medicine patents which were not protected before.作者: grieve 時(shí)間: 2025-3-24 13:54
Die Entwicklung des Hochtemperaturreaktors,e use of compulsory licensing. It is found that while the EU has built an image as a quiet and tactful player, WIPO displays subtle opposition to compulsory licensing. The WHO attempts to maintain a neutral stance in the ongoing deliberations while the NGOs want to dismantle any barriers to the access to medicines created by TRIPS.作者: Scintillations 時(shí)間: 2025-3-24 18:26
https://doi.org/10.1007/978-3-030-84193-5TRIPS flexibilities; Trade-Related Aspects of Intellectual Property Rights; public health; compulsory l作者: BINGE 時(shí)間: 2025-3-24 21:25
978-3-030-84195-9The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerl作者: myelography 時(shí)間: 2025-3-24 23:16 作者: Androgen 時(shí)間: 2025-3-25 05:22 作者: 截?cái)?nbsp; 時(shí)間: 2025-3-25 07:56 作者: 梯田 時(shí)間: 2025-3-25 13:32 作者: 供過(guò)于求 時(shí)間: 2025-3-25 18:58
The Development of Compulsory Licensing in International Patent Laws, Doha Declaration which clarifies Article 31. A significant attention will be paid to Article 31 because it sets out the procedure to issue a compulsory licence. As seen in Chapter .?how the patent system has considerably changed from Paris to TRIPS, this chapter also reveals a paradigm shift in the compulsory licensing regime.作者: 誹謗 時(shí)間: 2025-3-25 21:19 作者: 得罪人 時(shí)間: 2025-3-26 02:50 作者: institute 時(shí)間: 2025-3-26 06:11 作者: chastise 時(shí)間: 2025-3-26 09:09
The Bilingualism Controversy: Les Préludes Doha Declaration which clarifies Article 31. A significant attention will be paid to Article 31 because it sets out the procedure to issue a compulsory licence. As seen in Chapter .?how the patent system has considerably changed from Paris to TRIPS, this chapter also reveals a paradigm shift in the作者: NOCT 時(shí)間: 2025-3-26 14:11
https://doi.org/10.1007/978-3-531-91596-8n Patent Controller, for the first time, granted a compulsory licence to Natco, a domestic generic firm, to manufacture Nexavar, a patented medicine owned by Bayer. While this historic decision seemed to herald a new era of compulsory licensing in the region, the Controller, unexpectedly, turned dow作者: 喊叫 時(shí)間: 2025-3-26 19:14 作者: exhilaration 時(shí)間: 2025-3-26 21:28 作者: calamity 時(shí)間: 2025-3-27 04:03
https://doi.org/10.1007/978-3-663-02731-7licence. It also reveals how the application of compulsory licensing in one country closely relates to its domestic implication of TRIPS and pharmaceutical manufacturing capacity. This chapter provides recommendations for other developing countries from the collective experience of India and Brazil.作者: agglomerate 時(shí)間: 2025-3-27 07:30 作者: 彎曲道理 時(shí)間: 2025-3-27 10:40 作者: 發(fā)牢騷 時(shí)間: 2025-3-27 16:52 作者: TAG 時(shí)間: 2025-3-27 18:15 作者: 冥界三河 時(shí)間: 2025-3-27 23:07
Compulsory Patent Licensing and Access to Medicines: A Silver Bullet Approach to Public Health?978-3-030-84193-5作者: 新字 時(shí)間: 2025-3-28 02:56
